ID   FDOVL
AC   CVCL_B7MN
DR   cancercelllines; CVCL_B7MN
DR   Wikidata; Q112929560
RX   Patent=CN110835623B;
RX   PubMed=36982170;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.15484.
CC   Population: Chinese.
CC   Doubling time: 87 hours (Patent=CN110835623B; PubMed=36982170).
CC   Sequence variation: Mutation; HGNC; HGNC:1100; BRCA1; Simple; p.Ile1432Thr (c.4295C>T); Zygosity=Homozygous (PubMed=36982170).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Cys702fs (c.2104_2111del); Zygosity=Heterozygous (PubMed=36982170).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu252del (c.754_756delCTC); ClinVar=VCV000998484; Zygosity=Heterozygous (PubMed=36982170).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: Metastatic; Pelvic lymph node; UBERON=UBERON_0015876.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 8
//
RX   Patent=CN110835623B;
RA   Jiang W., Yang H.-J., Yang W.-T., Xiang L.-B., Zheng Y.-Y., He T.-C.,
RA   Pei X.;
RT   "Primary platinum-resistant human ovarian cancer cell line FDOVL, and
RT   preparation method and application thereof.";
RL   Patent number CN110835623B, 30-Aug-2022.
//
RX   PubMed=36982170; DOI=10.3390/ijms24065091; PMCID=PMC10049685;
RA   Jiang W., Ouyang X.-Y., Jiang C.-J., Yin L.-N., Yao Q.-L., Pei X.,
RA   Ji Z.-D., Li M., Song S.-L., Yang W.-T., Huang S.-L., Yang H.-J.,
RA   Shan B.-E.;
RT   "A NOTCH1 mutation found in a newly established ovarian cancer cell
RT   line (FDOVL) promotes lymph node metastasis in ovarian cancer.";
RL   Int. J. Mol. Sci. 24:5091.1-5091.19(2023).
//